tag:www.gov.uk,2005:/drug-safety-updateDrug Safety Update about General practice2025-05-07T13:59:47+01:00HM Governmenttag:www.gov.uk,2005:/drug-safety-update/kaftriov-ivacaftor-tezacaftor-elexacaftor-risk-of-psychological-side-effects2025-05-07T13:59:47+01:00Kaftrio� (Ivacaftor, tezacaftor, elexacaftor): risk of psychological side effectsPsychological side effects such as anxiety, low mood, sleep disturbance, poor concentration, and forgetfulness have been infrequently reported in people with cystic fibrosis treated with Kaftrio. Healthcare professionals sho�tag:www.gov.uk,2005:/drug-safety-update/short-acting-beta-2-agonists-saba-salbutamol-and-terbutaline-reminder-of-the-risks-from-overuse-in-asthma-and-to-be-aware-of-changes-in-the-saba-prescribing-guidelines2025-04-24T12:02:48+01:00Short-acting beta 2 agonists (SABA) (salbutamol and terbutaline): reminder of the risks from overuse in asthma and to be aware of changes in the SABA prescribing guidelinesHealthcare professionals and patients are reminded of the risk of severe asthma attacks and increased mortality associated with overuse of SABA with or without anti-inflammatory maintenance therapy in patients with asthma. H�tag:www.gov.uk,2005:/drug-safety-update/fezolinetantv-veoza-risk-of-liver-injury-new-recommendations-to-minimise-risk2025-04-10T12:00:08+01:00Fezolinetant�(Veoza): risk of liver injury; new recommendations to minimise riskFezolinetant treatment is associated with a risk of drug induced liver injury. New recommendations have been introduced to minimise this risk. Liver function should be monitored before and during treatment in all patients ta�